Invivyd’s (IVVD) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Invivyd (NASDAQ:IVVD) in a report published on Monday morning,Benzinga reports. They currently have a $9.00 target price on the stock.

A number of other analysts have also commented on IVVD. Morgan Stanley reduced their price target on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a research note on Wednesday, November 20th. EF Hutton Acquisition Co. I upgraded shares of Invivyd to a “strong-buy” rating in a report on Wednesday, October 30th. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Invivyd in a research note on Tuesday, February 4th. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Invivyd presently has an average rating of “Buy” and a consensus price target of $7.89.

Invivyd Price Performance

Invivyd stock opened at $1.23 on Monday. Invivyd has a one year low of $0.35 and a one year high of $4.74. The business’s fifty day moving average is $0.84 and its 200 day moving average is $0.87. The stock has a market capitalization of $147.13 million, a PE ratio of -0.63 and a beta of 0.61.

Insider Buying and Selling

In other Invivyd news, Director Terrance Mcguire sold 160,400 shares of the stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $0.59, for a total value of $94,636.00. Following the transaction, the director now directly owns 4,202,679 shares in the company, valued at approximately $2,479,580.61. This trade represents a 3.68 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last quarter, insiders have sold 816,466 shares of company stock valued at $423,214. 17.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Invivyd

A number of hedge funds have recently modified their holdings of IVVD. Proficio Capital Partners LLC purchased a new position in Invivyd during the third quarter valued at $27,000. Jane Street Group LLC raised its stake in shares of Invivyd by 290.5% in the fourth quarter. Jane Street Group LLC now owns 117,432 shares of the company’s stock worth $52,000 after buying an additional 87,358 shares during the period. Barclays PLC lifted its position in shares of Invivyd by 179.6% during the 3rd quarter. Barclays PLC now owns 117,973 shares of the company’s stock valued at $120,000 after buying an additional 75,780 shares in the last quarter. Renaissance Technologies LLC bought a new position in shares of Invivyd during the 4th quarter valued at approximately $74,000. Finally, JPMorgan Chase & Co. increased its holdings in Invivyd by 644.1% in the 4th quarter. JPMorgan Chase & Co. now owns 256,900 shares of the company’s stock worth $114,000 after acquiring an additional 222,375 shares in the last quarter. Institutional investors own 70.36% of the company’s stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.